1
EXHIBIT 10.19
CONFIDENTIAL TREATMENT
REQUESTED
***** Certain information on this page has been The asterisked portions of this REDACTED FOR
omitted and filed separately with the document have been omitted and are CONFIDENTIALITY
Securities and Exchange Commission. filed separately with the Securities
Confidential treatment has been requested and Exchange Commission.
with respect to the omitted portions.
AMENDMENT NO. 2 TO
COLLABORATION AND LICENSE AGREEMENT
This Amendment No. 2 to Collaboration and License Agreement is made as of
July __, 1998, by and among SmithKline Xxxxxxx Corporation, a Pennsylvania
corporation with offices at Xxx Xxxxxxxx Xxxxx, Xxxxxxxxxxxx, Xxxxxxxxxxxx
00000; SmithKline Xxxxxxx plc. an English corporation with its principal offices
at Xxx Xxxxxxxx Xxxxx, Xxxxxxxxx, Xxxxxxxxx, XX0 0XXX, Xxxxxxx; Incyte
Pharmaceuticals, Inc., a Delaware corporation with offices at 0000 Xxxxxx Xxxxx,
Xxxx Xxxx, Xxxxxxxxxx 00000; and diaDeXus, a Delaware limited liability company
with offices at 0000 Xxxxx Xxxxxxxxx, Xxxxx 000, Xxxxx Xxxxx, Xxxxxxxxxx 00000.
The parties to this Amendment No. 2 are parties to a Collaboration and
License Agreement, dated as of September 2, 1997, as amended by that certain
Amendment dated as of February 28, 1998 (the "Collaboration Agreement");
NOW, THEREFORE, the parties hereby agree as follows:
1. Appendix C, "Incyte Diagnostic Patents", is hereby amended to delete
the patents and patent applications listed in Attachment 1 to this Amendment
No. 2, which patents and patent applications are solely related to **********
2. Except as modified by this Amendment No. 2, the Collaboration Agreement
remains in effect pursuant to its terms.
IN WITNESS WHEREOF, the parties, through their authorized representatives,
have executed this Amendment No. 2 as of the date first written above.
SmithKline Xxxxxxx Corporation
By /s/ [SIGNATURE ILLEGIBLE]
-----------------------------
SmithKline Xxxxxxx plc
By /s/ [SIGNATURE ILLEGIBLE]
-----------------------------
Incyte Pharmaceuticals, Inc.
By /s/ [SIGNATURE ILLEGIBLE]
-----------------------------
diaDeXus, LLC
By /s/ [SIGNATURE ILLEGIBLE]
-----------------------------
2
Attachment 1
File Patent
Country Ref.# Type Filing Date Serial No. Issue Date No. Status
------------------ ----- ---- ----------- ---------- ---------- ------ ------
Australia ***** DCA 02/14/90 ***** 07/19/94 ***** Issued
Australia ***** DCA 08/13/91 ***** 06/29/95 ***** Issued
Australia ***** DCA 09/28/92 ***** 02/27/96 ***** Issued
Australia ***** DCA 07/01/94 ***** Pending
Australia ***** DCA 04/29/94 ***** Pending
Canada ***** DCA 02/14/90 ***** Pending
Canada ***** DCA 08/13/91 ***** Pending
Canada ***** DCA 09/28/92 ***** Pending
Canada ***** DCA 07/01/94 ***** Pending
Canada ***** DCA 04/29/94 ***** Pending
European Patent CO ***** DCA 02/14/90 ***** Pending
European Patent CO ***** DCA 08/13/91 ***** Pending
European Patent CO ***** DCA 09/28/92 ***** Pending
European Patent CO ***** DCA 07/01/94 ***** Published
European Patent CO ***** DCA 04/29/94 ***** Pending
Israel ***** DCA 02/12/90 ***** Pending
Japan ***** DCA 02/14/90 ***** Pending
Japan ***** DCA 08/13/91 ***** Pending
Japan ***** DCA 09/28/92 ***** Pending
Japan ***** DCA 07/11/94 ***** Pending
Japan ***** DCA 00/00/00 ***** Xxxxxxx
Xxxxx Xxxxx ***** DCA 00/00/00 ***** Xxxxxxx
Xxxxx Xxxxx ***** DCA 00/00/00 ***** Xxxxxxx
Xxx Xxxxxxx ***** DCA 02/13/90 ***** Pending
***** Certain information on this page has been omitted and filed separately
with the Securities and Exchange Commission. Confidential treatment has
been requested with respect to the omitted portions.
3
Attachment 1
File Patent
Country Ref.# Type Filing Date Serial No. Issue Date No. Status
------------------ ----- ---- ----------- ---------- ---------- ------ ------
United States ***** NEW 00/00/00 ***** Xxxxxxxxx
Xxxxxx Xxxxxx ***** CIP 00/00/00 ***** Xxxxxxxxx
Xxxxxx Xxxxxx ***** CIP 04/05/91 ***** 12/15/92 **** Issued
United States ***** CIP 00/00/00 ***** Xxxxxxxxx
Xxxxxx Xxxxxx ***** DCA 00/00/00 ***** Xxxxxxxxx
Xxxxxx Xxxxxx ***** CIP 00/00/00 ***** Xxxxxxx
Xxxxxx Xxxxxx ***** CIP 00/00/00 ***** Xxxxxxxxx
Xxxxxx Xxxxxx ***** DCA 00/00/00 ***** Xxxxxxxxx
Xxxxxx Xxxxxx ***** CIP 00/00/00 ***** Xxxxxxxxx
Xxxxxx Xxxxxx ***** DCA 00/00/00 ***** Xxxxxxx
Xxxxxx Xxxxxx ***** CIP 01/22/90 ***** 02/18/92 Issued
United States ***** DIV 12/14/92 ***** 05/03/94 Issued
United States ***** DIV 12/14/92 ***** 08/02/94 Issued
United States ***** CIP 00/00/00 ***** 00/00/00 Xxxxxx
Xxxxxx Xxxxxx ***** CON 00/00/00 ***** Xxxxxxx
Xxxxxx Xxxxxx ***** CON 00/00/00 ***** Xxxxxxx
Xxxxxx Xxxxxx ***** CON 04/18/97 ***** Pending
WIPO ***** CEQ 02/14/90 ***** Pending
WIPO ***** CEQ 08/13/91 ***** Pending
WIPO ***** CEQ 09/28/92 ***** Pending
WIPO ***** CEQ 07/01/94 ***** Pending
WIPO ***** CEQ 04/29/94 ***** Pending
WIPO ***** CEQ 05/01/95 ***** Pending
***** Certain information on this page has been omitted and filed separately
with the Securities and Exchange Commission. Confidential treatment has
been requested with respect to the omitted portions.
